(1) Change in BMD in LS measured by DXA at baseline, 6 mo and 12 mo. (2) Changes in serum calcium and phosphorus and bone turnover markers at 1 wk, 6 mo and 12 mo. (3) Changes in the components of the serum lipid profile (4) AEs
(1) Change in BMD in LS, FN, TH, and HT measured by DXA at baseline, 6 mo and 12 mo. (2) Change in serum ALP, urinary NTx/Cr at 6 mo and 12 mo. (3) AEs
Aln 70 mg/week or Rlx 60 mg/day or both for 12 months
12
1500 mg Ca plus 400 U vit D
(1) Change in BMD in TH, LS, and FN measured by DXA at baseline, 6, and 12 mo. (2) Changes in serum ALP, NTx/Cr at 1 wk, 6 mo, and 12 mo. (3) Changes in the components of the serum lipid profile (4) AEs
23.9%/29.5% 13/11
None
Aln: alendronate; Rlx: raloxifene; SD: standard deviation; BMI: body mass index; BMD: bone mineral density; RCT: radomized controlled trials; LS: lumbar spine; mo: months; NR: not reported; Ca: calcium; Vit D: vitamine D; DXA: dual-energy X-ray absorptiometry; TH: total hip; FN: femoral neck; NTx/Cr: urinary cross-linked N-telopeptide of type 1 collagen corrected to creatinine (Cr) excretion; ALP: serum bone-specific alkaline phosphatase; AEs: adverse events.
#The fracure data in Johnell's study were not reported in his original article but were cited by Recker's papers and then were extracted and pooled.
$The dose of calcium or vitamine D was not clearly stated.